Morphic Therapeutic
Pharmaceuticals, 35 Gatehouse Dr # A2, Waltham, Massachusetts, 02451, United States, 51-200 Employees
Phone Number: 78********
Who is MORPHIC THERAPEUTIC
Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer...
Read More
-
Headquarters: 35 Gatehouse Dr # A2, Waltham, Massachusetts, 02451, United States
-
Date Founded: 2015
-
Employees: 51-200
-
Revenue: $50 Million to $100 Million
-
Active Tech Stack: See technologies
-
CEO:
Praveen Tipirneni
Email
Phone
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 561110 |
Show More
Does something look wrong? Fix it. | View contact records from MORPHIC THERAPEUTIC
Morphic Therapeutic Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Morphic Therapeutic
Answer: Morphic Therapeutic's headquarters are located at 35 Gatehouse Dr # A2, Waltham, Massachusetts, 02451, United States
Answer: Morphic Therapeutic's phone number is 78********
Answer: Morphic Therapeutic's official website is https://morphictx.com
Answer: Morphic Therapeutic's revenue is $50 Million to $100 Million
Answer: Morphic Therapeutic's SIC: 2834
Answer: Morphic Therapeutic's NAICS: 561110
Answer: Morphic Therapeutic has 51-200 employees
Answer: Morphic Therapeutic is in Pharmaceuticals
Answer: Morphic Therapeutic contact info: Phone number: 78******** Website: https://morphictx.com
Answer: Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. Despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month